Provided by Tiger Trade Technology Pte. Ltd.

United Therapeutics

510.38
-5.0800-0.99%
Post-market: 513.002.62+0.51%16:26 EDT
Volume:536.22K
Turnover:273.89M
Market Cap:21.89B
PE:18.26
High:515.55
Open:510.95
Low:507.03
Close:515.46
52wk High:609.35
52wk Low:375.61
Shares:42.89M
Float Shares:39.35M
Volume Ratio:1.27
T/O Rate:1.36%
Dividend:- -
Dividend Rate:- -
EPS(TTM):27.95
EPS(LYR):27.86
ROE:19.31%
ROA:11.61%
PB:3.42
PE(LYR):18.32

Loading ...

United Therapeutics (UTHR) Will Present Phase 3 Data At European Congresses

Simply Wall St.
·
Aug 30

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 7,500 Common Shares for $3.93 Million

Reuters
·
Aug 29

United Therapeutics Submits FDA NDA for PAH Drug Ralinepag

Reuters
·
Aug 28

RBC Capital Sticks to Its Buy Rating for United Therapeutics (UTHR)

TIPRANKS
·
Aug 27

United Therapeutics Chairperson, CEO Rothblatt Sells 9,500 Shares for $4.92 Million

Reuters
·
Aug 27

United Therapeutics Chairperson and CEO Martine A. Rothblatt Reports Disposal of Common Shares Worth $5,031,247.39

Reuters
·
Aug 25

Analysts Offer Insights on Healthcare Companies: United Therapeutics (UTHR) and AdaptHealth (AHCO)

TIPRANKS
·
Aug 24

United Therapeutics Says FDA Accepts Ralinepag NDA for Pulmonary Arterial Hypertension

Reuters
·
Aug 24

United Therapeutics Corporation: Ralinepag Has not Been Approved for Use in Any Indication by FDA and Remains Investigational for Pah

THOMSON REUTERS
·
Aug 24

United Therapeutics Corporation Announces FDA Filing Acceptance of New Drug Application for Ralinepag to Treat Pulmonary Arterial Hypertension

THOMSON REUTERS
·
Aug 24

United Therapeutics Corporation - FDA Sets Pdufa Target Action Date for Ralinepag on June 24, 2027

THOMSON REUTERS
·
Aug 24

United Therapeutics Chairperson, CEO Martine Rothblatt Disposes of 9,500 Common Shares for $5.01 Million

Reuters
·
Aug 21

United Therapeutics CEO Martine Rothblatt Disposes of 9,500 Shares for $4.79 Million

Reuters
·
Aug 19

United Therapeutics announces full enrollment in TETON-PPF study

TIPRANKS
·
Aug 17

United Therapeutics Seeks FDA Priority Review for Tyvaso Label Expansion in IPF

Reuters
·
Aug 17

United Therapeutics Corporation Announces Full Enrollment of the Teton-Ppf Study of Inhaled Treprostinil for the Treatment of Progressive Pulmonary Fibrosis

THOMSON REUTERS
·
Aug 17

United Therapeutics Corporation - Topline Data from Teton-Ppf Study Expected in Second Half of 2027

THOMSON REUTERS
·
Aug 17

United Therapeutics CEO Chair Martine Rothblatt Disposes of 9,500 Shares for $4.81 Million

Reuters
·
Aug 15

United Therapeutics Chairperson and CEO Martine Rothblatt Disposes of 8,500 Common Shares Worth $4.45 Million

Reuters
·
Aug 13

United Therapeutics CEO Chairperson Martine Rothblatt Disposes of 9,500 Shares Worth $5.03 Million

Reuters
·
Aug 11